Brigatinib
pan-ALK inhibitor / A potent and selective pan-ALK inhibitor IC50=0.6 nM.1 Cells with ALK mutation L1196Q2 and the double mutation I1171S + G12693 remain sensitive to brigatinib. Clinically useful in non-small cell lung cancer.4
Biochemicals & reagents
1197953-54-0
AP26113
1) Zhang et al. (2016), The potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models; Clin. Cancer Res., 22 5527 2) Ceccon et al. (2013), Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors; Mol. Cancer Res., 11 122 3) Takahashi et al. (2020), Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer; Thorac. Cancer., 11 581 4) Pinto et al. (2020), Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer; Respir. Med. , 14 385
-20°C
TARGET: Kinase -- PATHWAY: EGF -- DISEASE AREA: Cancer